Posts

BeOne Streamlines Oncology Pipeline: Shelves CDK2 and KRAS Inhibitors, Advances Degraders

on
BeOne deprioritized CDK2 inhibitor BG-68501 (Ph1 solid tumors) in favor of CDK2 degrader BG-75098 (Ph1, entered clinic end-2025, tested in breast cancer/solid tumors with improved CDK2 vs CDK1 selectivity). Dropped pan-KRAS inhibitor BGB-53038 (Ph1 KRAS-mutant solids, combos with Tevimbra/Erbitux) for preclinical KRAS degrader (clinical development H2 2026). Terminated EGFR degrader BG-60366 Ph1 trial in EGFRm NSCLC (enrollment halted at 33/93 patients, status paused for data review). Sidelined MAT2A inhibitor BG-89894 (Ph1 solids, licensed from CSPC), raising questions for related PRMT5 inhibitor BGB-58067 (Ph1, combos including with MAT2A). Confirmed termination of anti-CCR8 MAb BGB-A3055 Ph1 trial but noted 'does not reflect discontinuation of the asset'; no direct mention of halting Ph2 RA trial in provided data. Sources:

FDA's Shock Rejection of Ebvallo Cell Therapy: Reconsideration Efforts and uniQure Concerns

on

Roche to Acquire PathAI for Up to $1.05 Billion to Enhance AI-Powered Diagnostics

on

Entrada's Stock Craters as DMD Data Underperform Expectations, Handing Advantage to Novartis

on

Digital Health Revolutionizing Chronic Disease Management and Prevention

on

Amgen Announces Additional $300M Investment in Puerto Rico Manufacturing Facility

on

High Turnover in Top FDA and CDC Roles: 15 Leaders in 18 Months Amid Leadership Instability

on

GSK Acquires $1B siRNA Deal from SiranBio for Obesity and Cardiometabolic Disease Treatment

on

Eli Lilly Invests Additional $4.5B in Indiana Manufacturing Facilities at LEAP District

on

PhRMA Launches Seven-Figure Ad Campaign Targeting 340B Drug Discount Program

on

Spago Nanomedical Interim Report January-March 2026

on

Recursion Reports Q1 2026 Financial Results and Business Update

on

Gaps and Scandals in the Underregulated Fertility and Surrogacy Industry

on